These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30735922)

  • 41. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Tiihonen J; Tanskanen A; Taipale H
    Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of 'all-cause discontinuation' of initial oral antipsychotic medication in first episode psychosis.
    Mustafa S; Joober R; Lepage M; Iyer S; Shah J; Malla A
    Schizophr Res; 2018 Nov; 201():287-293. PubMed ID: 29706449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
    Taylor DM; Young CL; Mace S; Patel MX
    J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
    Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
    Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
    J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.
    Voss EA; Ryan PB; Stang PE; Hough D; Alphs L
    Int Clin Psychopharmacol; 2015 May; 30(3):151-7. PubMed ID: 25730525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
    Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
    Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
    Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
    J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.